• AMPLIRUN® ZIKA VIRUS
    RNA CONTROL

    Guarantee the quality of
    your molecular assays


  • New ZIKV-DENV-CHIKV IFA
    Easy-to-read results for the differential
    serological diagnosis by immunofluorescence


  • VirClia®
    Chemiluminescence in Monotest.
    The perfect combination for infectious serology.


  • Respiratory virus testing
    The complete solution for respiratory virus testing;
    screening and identification


Featured product

VIRCLIA® PLUS

VIRCLIA® PLUS

ECCMID 2017

Vircell will once again be attending the European Congress of Clinical Microbiology and Infectious Diseases. We would be pleased to welcome you at our stand!

Vienna, 22-25 April 2017, Stand #82

More information

Development and production of diagnostic reagents for human infectious diseases

Vircell is a biotechnology company specialized in the development and production of ready to use reagents for human infectious diseases. We are present in laboratories of more than 80 countries worldwide on five continents. Vircell offers more than 400 references for the detection of bacteria, viruses, parasites and fungi by means of different techniques: ELISA, chemiluminescence, direct and indirect immunofluorescence, immunocapture agglutination, cell culture and Molecular Biology (oligochromatography and PCR controls).

Distributors

Vircell is present in laboratories of more than 80 countries worldwide. International Sales constitute one of the major sources of income for the company thanks to the constant work of our commercial team, who has a deep knowledge of the international market. If you need further information on the distribution of our products in your country, do not hesitate to contact us.

More information
10 April 2017 MEDLAB Asia Pacific 2017 Great success at MEDLAB Asia Pacific 2017 trade show From the 3rd to the 5th ...
22 April 2017 ECCMID 2017 Vircell will once again be attending the ECCMID Congress this spring, which will take place ...

Newsletter

Sign up for our newsletter and you will receive our latest news in your e-mail